These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3318089)

  • 21. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Lamm DL
    J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
    Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
    Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
    Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder tumors. Ablative and prophylactic effects of intravesical BCG on papillary tumors].
    Hagiwara M; Ohigashi T; Nakazono M; Asakura H; Tsukamoto T; Iigaya T; Yamamoto T; Shishido S; Hayashi A; Yamamoto H
    Nihon Hinyokika Gakkai Zasshi; 1988 Mar; 79(3):521-6. PubMed ID: 3221605
    [No Abstract]   [Full Text] [Related]  

  • 28. Intravesical BCG therapy in the management of multiple superficial bladder carcinoma. Comparison between Glaxo and Pasteur strains.
    Kaisary AV
    Br J Urol; 1987 Jun; 59(6):554-8. PubMed ID: 3690187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
    deKernion JB; Huang MY; Lindner A; Smith RB; Kaufman JJ
    J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Bladder cancer BCG Study Group].
    Akaza H; Kameyama S; Kakizoe T; Kojima H; Koiso K; Aso Y; Niijima T
    Nihon Hinyokika Gakkai Zasshi; 1992 Feb; 83(2):183-9. PubMed ID: 1556836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer.
    Herr HW; Laudone VP; Badalament RA; Oettgen HF; Sogani PC; Freedman BD; Melamed MR; Whitmore WF
    J Clin Oncol; 1988 Sep; 6(9):1450-5. PubMed ID: 3418376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; Li ML
    Jpn J Clin Oncol; 2004 Apr; 34(4):202-5. PubMed ID: 15121756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
    Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
    N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin.
    Bretton PR; Herr HW; Kimmel M; Whitmore WF; Laudone V; Oettgen HF; Fair WR
    J Urol; 1990 Apr; 143(4):710-2; discussion 712-3. PubMed ID: 2313796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model.
    Steinberg GD; Brendler CB; Squire RA; Isaacs JT
    J Urol; 1991 Mar; 145(3):647-53. PubMed ID: 1997724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
    Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
    Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials.
    De Jager R; Guinan P; Lamm D; Khanna O; Brosman S; De Kernion J; Williams R; Richardson C; Muenz L; Reitsma D
    Urology; 1991 Dec; 38(6):507-13. PubMed ID: 1836081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma.
    D'Ancona CA; Netto Júnior NR; Claro JA; Ikari O
    J Urol; 1991 Mar; 145(3):498-501. PubMed ID: 1997698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
    Witjes JA; vd Meijden AP; Debruyne FM
    Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.